Posted by Michael Wonder on 06 Oct 2022
US FDA accepts Takeda’s supplemental biologics license application for use of Takzyro (lanadelumab-flyo) to prevent hereditary angioedema attacks in children 2 years of age and older
5 October 2022 - Filing is based on data from Phase 3 SPRING study in paediatric patients 2 to <12 years of age.
Takeda today announced that the US FDA has accepted a supplemental biologics license application for the potential expanded use of Takhzyro (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema in paediatric patients 2 to <12 years of age.
